ZoBio is excited to attend TFMED 2026, a four-day transdisciplinary conference dedicated to next-generation therapeutic modalities, including molecular glues, PROTACs, nucleic acid-based therapies, and cell-based approaches.

The meeting brings together researchers, clinicians, and industry experts, offering in-depth scientific sessions, direct interaction with leading specialists, and valuable opportunities for networking and collaboration, with a strong focus on early-career scientists.

In person Molecular glues and targeted protein degraders are revolutionizing the field of drug discovery, offering promising solutions for a range of diseases, including cancer, infectious, inflammatory, and neurodegenerative diseases. These innovative therapies are particularly beneficial for targeting previously “undruggable” pathogenic proteins. The recent emergence of the ‘molecular glue’ class of protein degraders is paving…

In person Starting from Sunday, November 10th, the ZoBio team participated in the 32nd Protein Structure Determination in Industry meeting, which was held at the Novotel Paris Centre Tour Eiffel in Paris, France. This year’s meeting was organized jointly by SERVIER and Synchrotron SOLEIL, with support from Hg3 Conferences. The scientific talks focused on the…